OX40, when paired with agents such as anti-CTLA-4, significantly enhances T-cell mediated antitumor responses, suggesting a synergistic potential that extends beyond monotherapy applications and correlates with improved GBM patient prognoses, with high OX40L mRNA levels in GBM linked to longer progression-free survival [57, 60–63]. The gene discussed is TNFSF4; the disease is glioblastoma.